Exploratory Efficacy Endpoints In The Community-Acquired Pneumonia Immunization Trial In Adults (Capita)

•The 23 remaining exploratory endpoints of CAPiTA are reported.•PCV13 efficacy was 28.9–75.0% and was significant for 8 exploratory endpoints.•Significant efficacy included all confirmed pneumococcal CAP and IPD episodes.•VT serotype 1 and 7F was most common among PCV13 and placebo vaccinees, respectively.•Findings support primary CAPiTA analysis showing PCV13 prevented VT-CAP and VT-IPD.